Mi nombre es Jose Luis Muñoz y soy químico desde hace 16 años, me especializo en la química orgánica y nanotecnología. Desde que comencé en la investigación me interesé por la síntesis orgánica relacionada con la industria farmacéutica. Mi propósito es el diseño de nuevas rutas y el estudio de escalabilidad de procesos para la preparación de activos de interés farmacéutico o en el sector de la salud.
Comencé como becario en la universidad de Barcelona en un proyecto asociado con enfermedades neurodegenerativas en el diseño de una biblioteca dinámica de compuestos mediante el intercambio tiol-disulfuro. Tras esta experiencia formé parte de Enantia, una pequeña empresa química en la que participé en multitud de proyectos asociados con empresas farmacéuticas tanto en la síntesis de pequeñas moléculas de alto valor añadido como en la preparación de subproductos y su completa caracterización. Además, adquirí los conocimientos y experiencia necesarios para realizar estudios de escalabilidad y transferencia tecnológica.
En la búsqueda de un mayor conocimiento en temas relacionados con la salud amplié mis conocimientos de química con un master en nanotecnología y el doctorado en los que trabajé, basándome en la química y la nanotecnología, en polímeros tipo dendrimérico con radicales aplicados a técnicas para el diagnóstico como Resonancia magnética de Imagen (MRI) o la Polarización dinámica nuclear (DNP) acoplada a MRI. Tras la etapa del doctorado me uní al grupo de seguridad de nanomateriales en LEITAT donde estudié en ciclo de vida de nanomateriales y sus posibles efectos con la salud y el medio ambiente, participando en proyectos internacionales como GuideNano, Nanosolutions y Porous4app entre otros. Finalmente, y dentro de LEITAT, pasé a formar parte del grupo de nanomedicina en el que, entre otras propuestas, se intentan solventar dificultades de moléculas activas, como la estabilidad o la solubilidad, mediante su encapsulación. En esta etapa he participado en proyectos como Nano4Derm, Acinetoclinic, nTrack o BioprintIa.
Preparation of radical dendrimers and application as molecular switches between radical and anionic states.
- Evaluation of magnetic properties SQUID
- Wettability studies
-EPR interactions among radicals intramolecular (inter radical distance and bond distance)
Application of organic radical compounds to improve medicinal sensibility by 13C pyruvic acid hyperpolarization- MRI or as T1 contrast agents in MRI.
. Preparation of persistent organic radicals (PTM, BDPA, TEMPO, and PROXYL), and characterization, including Electron Paramagnetic Resonance (EPR).
. Synthesis and surface modification of phosphorous dendrimers. . Application of diradicals in Dynamic Nuclear Polarization (DNP) and MAS-NMR-DNP.
. Water-soluble radical dendrimers testing for T1 MRI contrast agents.
Dynamic library of compounds through a thiol-disulfide bond exchange of RNA stem-loop structure targeting.
. Solid-state synthesis (Fmoc/tBu y Boc/Bz) of peptide derivatives.
. Liquid phase synthesis (Fmoc/tBu y Boc/Bz) of neomycin-thiol derivatives and 2-dexoxystreptamine disulphur compounds
. Solid-phase synthesis of polypyrrole; Purification by preparative HPLC.
. Characterizations by RMN y EM MALDI-TOF.
Exploiting the improved and novel properties of materials at the nanoscale on nanotechnology applications for delivery of therapeutics and biosensing or medical diagnostics.
. Proposals preparation, activities execution, and data collection for deliverables. Participation in European framework programs (H2020,
Horizon Europe, ERANETs) national (PID/ RETOS/Misiones) and private market projects.
. Diagnostics and theragnostic metallic nanoparticles synthesis and surface biomodification for in vitro and in vivo applications.
. Smart delivery, drug protection, and pharmacokinetics/pharmacodynamics modification through polymeric encapsulation with different methodologies (ionic gelation, sol-gel interfacial polymerization, solvent evaporation, etc).
. Complete characterization of Nanomaterials
and nanocarriers, such as morphology characterization (TEM/SEM, DLS, ζ potential, Nanosight), thermal properties (TGA/DSC), and others (NMR, IR, UV, etc).
Technological support to industries to ensure that their technology based-products and processes are safe for human health and the environment.
. Safety assessment of nanomaterial or materials containing nanomaterials performing aging studies simulating different stages of their life cycle from different matrices and processes.
. Materials characterization for substance registration dossier following European Chemical Agency (ECHA).
. Proposals preparation, activities execution, and data collection for deliverables. Participation in European framework programs (NP7 and
H2020) national (PID/ RETOS) and private market projects.
. Materials, nanomaterials, and released fractions morphology characterization (TEM/SEM, DLS, ζ potential, Nanosight), thermal properties (TGA/DSC), and others (NMR, IR, UV, etc).
Organic synthesis at the medium and small scale of new products, intermediates, and side products with high added value. Enantiopurity
. Development of new synthetic pathways.
. Verification of synthetic procedures.
. Colorimetric validations under pharmaceutical guidelines.
Application of organic radical compounds to improve medicinal sensibility by 13C pyruvic acid hyperpolarization- MRI or as T1 contrast agents in MRI.
. Preparation of persistent organic radicals (PTM, BDPA, TEMPO, and PROXYL), and characterization, including Electron Paramagnetic Resonance (EPR).
. Synthesis and surface modification of phosphorous dendrimers.
. Application of diradicals in Dynamic Nuclear Polarization (DNP) and MAS-NMR-DNP.
. Water-soluble radical dendrimers testing for T1 MRI contrast agents.
. Process improvement and development of new synthetic strategies for Medicinal Chemistry and Chemical R&D.
. Synthesis and characterization of new compounds with potential pharmaceutical applications and high added value.
. Research and development pathways of enantioselective products for varied industrial applications.
. Impurities identification, isolation, and evaluation of parameters related to its formation.
. Evaluation of Scale-Up processes
Dynamic library of compounds through a thiol-disulfide bond exchange of RNA stem-loop structure targeting.
. Solid-state synthesis (Fmoc/tBu y Boc/Bz) of peptide derivatives.
. Liquid phase synthesis of acridine derivatives.
. Solid-phase synthesis of polypyrrole; Purification by preparative HPLC.
. Characterizations by RMN y EM MALDI-TOF